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Available online 9 December 2015Background: Patients with schizophrenia spectrum disorders and substance usemay have an earlier onset of illness
compared to those without substance use. Most previous studies have, however, too small samples to control for
confounding variables and the effect of speciﬁc types of substances. The present study aimed to examine the rela-
tionship between substance use and age at onset, in addition to the inﬂuence of possible confounders and speciﬁc
substances, in a large and heterogeneous multisite sample of patients with schizophrenia spectrum disorders.
Methods: The patients (N=1119)were recruited from catchment areas in Oslo, Stavanger and Bergen, Norway, di-
agnosed according to DSM-IV and screened for substance use history. Linear regression analysis was used to exam-
ine the relationship between substance use and age at onset of illness.
Results: Patients with substance use (n = 627) had about 3 years earlier age at onset (23.0 years; SD 7.1) than the
abstinent group (n= 492; 25.9 years; SD 9.7). Only cannabis use was statistically signiﬁcantly related to earlier age
at onset. Gender or family history of psychosis did not inﬂuence the results.
Conclusion: Cannabis use is associated with 3 years earlier onset of psychosis.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Substance use1. Introduction
Patients with schizophrenia spectrum disorders and substance use
seem to have an earlier age at onset of their illness than patientswithout
substance use. This hasmost consistently been shown in relation to can-
nabis use (Barnes et al., 2006; Barnett et al., 2007; Bhavsar, 2015;
Donoghue et al., 2014; Large et al., 2011; Mane et al., 2015; Myles
et al., 2012; Power et al., 2013; Tosato et al., 2013) and to some degree
to use of stimulants such as amphetamines, cocaine and ecstasy
(Power et al., 2013; van der Meer et al., 2014). Most studies have, how-
ever, too small samples to investigate the effect of speciﬁc types of sub-
stances. Large et al. (2011) tried to examine the effects of speciﬁc
substances by mean of a meta-analysis; a 2 and 2.7 years earlier age at
onset was reported for unspeciﬁed substance use and cannabis use, re-
spectively. The effect of cannabis was emphasized by the authors, butaukeland University Hospital,
. This is an open access article underalso the need for large scale samples to analyze individual data (Large
et al., 2011).
Moreover, theremay be characteristics that are associatedwith both
substance use and age at onset that confound this relationship. An asso-
ciation between earlier age at onset and a family history of psychosis has
been reported (McInnis et al., 1999), and a higher familial vulnerability,
i.e. having a higher distribution of relatives with psychosis, in substance
using patients has been suggested (McGuire et al., 1995). Gender might
also be a confounder, as males have both earlier age at onset and more
substanceuse (Abel et al., 2010). In conclusion, there is still considerable
ambiguity concerning the association between substance use and age at
onset.
Themain aims of this studywere to: 1) examine the relationship be-
tween substance use and age at onset, in addition to the inﬂuence of
possible confounders, in schizophrenia spectrum disorders, 2) examine
the effect of speciﬁc substance use, such as cannabis, stimulants, co-
caine, opiates and hallucinogens, on this relationship. In order to
achieve this, a large and heterogeneous multisite sample of patients
with schizophrenia spectrum disorders was included.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Overview
Data from three different clinical research sites in Norwaywas used:
the Thematically Organized Psychosis Study (TOP study) Oslo area (n=
873), 2000–2012; Early Treatment and Intervention in Psychosis study
(TIPS-II study), Rogaland area (n = 185), 2001–2012; and the Bergen
Psychosis Project 2, (BP2 study, 2012–2013; Neurocognition of Schizo-
phrenia (NOS study, 2000–2002)), Bergen area (n = 71). Inclusion
criteria were: a DSM-IV diagnosis of schizophrenia, schizophreniform
disorder, schizoaffective disorder, delusional disorder, brief psychotic
disorder and psychosis not otherwise speciﬁed, living in the respective
catchment areas and age 18–65 years. Patients were excluded from
the study if they had a history of moderate/severe head injury, neuro-
logical disorder, or if they did not speak a Scandinavian language (Joa
et al., 2008; Lagerberg et al., 2011; Løberg and Hugdahl, 2009).
Patients in all of the three samples gave informed consent and the
respective projects were approved by the Regional Committee for Med-
ical Research Ethics and the Norwegian Data Inspectorate.
2.2. Clinical assessments
Diagnoses were evaluated by means of the Structured Clinical Inter-
view for DSM-IV (SCID) (First et al., 1995), modules A–E, administered
by trained clinical psychologists and psychiatrists. The inter-rater reli-
ability of diagnosis has been reported to be high in both the TOP,
Kappa value of 0.77 (Ringen et al., 2008) and the TIPS-II study, Kappa
value of 0.9 (Weibell et al., 2013). There was no measure of reliability
for diagnosis from the Bergen Psychosis Project 2. All the raters in the
TOP and TIPS-II study completed training courses in SCID assessments
and there has been a cooperation between the two sites with regard
to inter-rater reliability and validity of clinical measures (Friis et al.,
2003). The Positive and Negative Syndrome Scale (PANSS) (Kay et al.,
1989)was used to rate psychotic symptoms at baseline in the respective
projects. Age at onset was deﬁned as the ﬁrst psychotic episode/and or
ﬁrst time the patient had a clinically signiﬁcantly score (≥4) on one or
more of the following items from the Positive and Negative Syndrome
Scale: Delusions, Hallucinatory behavior, Grandiosity, Suspiciousness/
Persecution, or Unusual thought content (Friis et al., 2003), with a dura-
tion of at least one week. The accuracy of the estimation of age at onset
was depending on the accessible information in each case. When age at
onset of psychotic symptoms was missing, which was the case for 18
patients, age of the ﬁrst consultation at psychiatric services due to psy-
chosis was used as a proxy for age at onset.
The Global Assessment of Functioning scale (GAF), split version, was
used to assess the general level of symptoms and functioning at baseline
(Pedersen et al., 2007). Family history of schizophrenia or bipolar disor-
der among ﬁrst degree relatives was obtained through patient inter-
views (i.e. mother, father, sisters and brothers). Patients having at
least one ﬁrst-degree relative with schizophrenia or bipolar disorder
were deﬁned as having a family history of psychosis. Age at initiation
of antipsychotic medication use was registered by examining journals
and interviewing patients.
Substance use was documented through interviews regarding life-
time use of substances, urine samples, and use of the Clinical Drug Use
Scale (DUS) and the Clinical Alcohol Use Scale (AUS) (Drake et al.,
1996; Drake et al., 1990). Substance use disorders were diagnosed
using the SCID-E module (First et al., 1995). All accessible information
in each case was examined to avoid false negative substance users. Pa-
tients' severity of alcohol use was rated on a 5-point scale (1 = absti-
nence, 2 = use without impairment, 3 = abuse, 4 = dependence,
5 = severe dependence) by use of AUS. The equivalent DUS rating
scale, was administrated for estimating severity of substance use
(Drake et al., 1996). The TIPS-II study (n = 216) only recorded use of
substances the last 6 months before inclusion and no lifetime substanceuse. Patientswere split into two groups; Substance andAbstinent, based
on whether or not they had ever used substances including cannabis,
amphetamines, cocaine, hallucinogens and opiates. Speciﬁcally, groups
were deﬁned on the fulﬁllment or not of at least one of the following
criteria: 1) a score of 2 or more on the Clinical Drug Use Scale 2) a
DSM-IV diagnosis of substance use, abuse or dependence 3) lifetime
registration of substance use and 4) positive results on urine tests for
substances. Thus, the Abstinent group had never used cannabis or any
other illicit substance that were recorded.
2.3. Statistical analyses
All statistical analyses were performed using SPSS software, version
21.0 (IBM). Categorical variables are presented in percentage and num-
ber. Descriptive continuous variables are presented by mean and stan-
dard deviation in the two groups. Independent t-tests and chi-square
analyses were used to examine differences in variables in the two
groups. Regression analyses were performed with age at onset as the
dependent variable and use of substances as the independent (predic-
tor) variable. Analyses were run separately in the respective samples
to examine if the relationship between the variable, age at onset and
use of substances, were the same before data were merged into one
dataset. These initial analyses conﬁrmed an association between age
at onset and use of substances in all samples, in the direction that sub-
stance use was associated with earlier age at onset. The data sets were
then merged and the regression analyses performed for the merged
sample. Preliminary analyses were conducted in the whole sample to
ensure that the assumptions of linearity, multi-collinearity and homo-
scedasticity were met. The skewness of 1.110, and kurtosis 1.701 of
the age at onset variable, indicate that the normality assumption was
not violated (Curran et al., 1996). There were missing in the following
variables: Family history of psychosis (113); Education, years (25); Du-
ration of illness, years (68); Agewhen startedusing anti-psychoticmed-
ication (186); Positive sub-scale (7); Negative sub-scale (9); General
psychopathology sub-scale (13); PANSS Total (19); GAF function score
(2); GAF symptom score (3); CDUS (140); CAUS (142). A stepwise re-
gression analysis was performedwhere age at onset was the dependent
variable and the following independent variables were entered in a
speciﬁed order: gender, use of alcohol (Clinical Alcohol Use Scale), use
of certain types of substances, such as cannabis, stimulants, cocaine, opi-
ates, and hallucinogens, and the interaction term between speciﬁc sub-
stances and gender. Pearson correlations (Pearson's r) were used to
assess bivariate associations between the predictor variables. Listwise
deletion in the regression analysis reduced the sample sizewhenmulti-
ple variables with missing cases were included. Speciﬁcally, a one way
between-groups analysis of covariance was used to examine whether
the effect of speciﬁc substances on age at onset remained signiﬁcant
after adjusting for a family history of psychosis.
3. Results
3.1. Groups comparisons on demographic and clinical characteristics
Patients in the two groups were compared on all demographic and
clinical characteristics (Table 1). There were more males in the Sub-
stance group; 67.8%, compared to the Abstinent group, 53.5%. A higher
proportion of the Abstinent group was diagnosed with schizoaffective
disorder; 15.4%, compared to the Substance group, 10.6%, and there
was a higher proportion of the Substance group, which was diagnosed
with psychotic disorder not otherwise speciﬁed; 19.9%, compared to
the Abstinent group, 12.0%. In addition, the Abstinent group patients
were older, had a higher mean total years of education, a longer mean
duration of illness, a higher mean age of initiating antipsychotic treat-
ment, a lower score on PANSS General Psychopathology scale and a
higher score on GAF functioning (see Table 1 for details). The Substance
Table 1
Demographic and clinical characteristics of abstinent and substance using patients.
Abstinent group
n (%)
Substance group
n (%)
P-value
Group distribution 492 (44.0%) 627 (56.0%)
Male 263 (53.5%) 425 (67.8%) .000⁎⁎
Schizophrenia 273 (55.6%) 361 (57.6%) .028⁎,a
Schizoaffective 76 (15.4%) 67 (10.6%)
Delusional disorder 38 (7.7%) 32 (5.1%) .001⁎,b
Psychosis not otherwise speciﬁed 59 (12.0%) 125 (19.9%)
Schizophreniform disorder 33 (6.7%) 23 (3.7%) .098c
Brief psychosis 13 (2.6%) 19 (3.0%)
Family history of psychosis 91 (20.7%) 101 (17.3%) .259
Mean (SD) Mean (SD)
Age 32.3 (11.2) 28.3 (8.3) .000⁎⁎
Education (years) 12.9 (3.0) 12.0 (2.6) .000⁎⁎
Age at onset of psychotic symptoms 25.9 (9.7) 23.0 (7.1) .000⁎⁎
Duration of illness, years 6.4 (7.9) 5.0 (6.2) .001⁎
Age when started using ap.d 28.0 (9.4) 25.1 (7.0) .000⁎⁎
PANSSe
Positive sub-scale 15.6 (5.5) 15.9 (5.3) .518
Negative sub-scale 15.1 (6.3) 15.6 (6.4) .163
Gen. psychopath. sub-scalef 31.5 (8.3) 32.5 (8.2) .042⁎
Total 62.4 (16.4) 64.2 (16.4) .086
GAF function scoreg 44.2 (11.3) 42.0 (11.3) .002⁎
GAF symptom score 40.8 (11.7) 40.2 (11.6) .441
CDUSh 1.0 (.0) 2.0 (1.1) .000⁎⁎
CAUSi 1.7 (.6) 2.1 (.7) .000⁎⁎
⁎ Signiﬁcant at the .05 level.
⁎⁎ Signiﬁcant at the .001 level.
a P-value for comparison of schizophrenia plus schizoaffective disorder.
b P-value for comparison of delusional plus psychosis not otherwise speciﬁed.
c P-value for comparison of schizophreniform disorder plus brief psychosis.
d Age when started using anti-psychotic medication.
e PANSS = Positive and Negative Syndrome Scale.
f Gen. psychopath. sub-scale = General Psychopathology sub-scale.
g GAF = the Global Assessment of Functioning.
h CDUS = Clinical Drug Use Scale.
i CAUS = Clinical Alcohol Use Scale.
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3.2. The association between age at onset and speciﬁc types of substances,
gender and family history
Bivariate analysis showed that the Substance group had an earlier
mean age at onset (M = 23.0; SD 7.1) compared to the Abstinent
group, 25.9 (SD 9.7). Thus, the patients with substance use had a
2.9 year earlier onset than the patients without substance use.
The result from the stepwise regression analysis including the vari-
ables gender, alcohol and speciﬁc substances is shown in Table 2. Of
note, neither gender, use of alcohol nor the interaction term between
gender and the speciﬁc substances were signiﬁcantly associated to ageTable 2
Results of stepwise regression analysis, including gender, alcohol use and illicit substances
(n = 977).
b SE-b Beta t P value 95% CI of B
Lower Upper
Constant 27.014 1.178 22.938 .000⁎⁎ 24.703 29.325
Gender −.555 .576 −.031 −.964 .335 −1.686 .575
Alcohol −.171 .419 −.013 −.409 .683 −.994 .651
Cannabis −2.648 .683 −.150 −3.876 .000⁎⁎ −.3.989 −1.307
Amphetamines .081 .921 .004 .088 .930 −1.726 1.889
Cocaine −.831 1.029 −.038 −.807 .420 −2.850 1.188
Hallucinogens .385 1.037 .017 .371 .711 −1.650 2.419
Opiates −1.045 1.055 −.036 −.991 .322 −3.115 1.025
The dependent variable was age at onset. R2 = .032, Adjusted R2 = .025.
⁎⁎ Signiﬁcant at the .001 level.at onset, thus these variables were removed. The re-estimated model
with the speciﬁc substances explained 2.9% of the variance in age at
onset, F (5, 1113) = 6.66, P = 0.001. Only cannabis, of all investigated
substances of use, was signiﬁcantly related to age at onset (beta =−
.16, P b 0.001). See Table 3 for bivariate correlations between the predic-
tor variables. Of note, there were moderate positive associations be-
tween use of cannabis and use of amphetamines, cocaine and
hallucinogens, whilst the association between cannabis and opiate use
was weak.
The effect of cannabis remained signiﬁcant, F (1, 1003) = 31.66, P b
0.001, and therewas nomain effect of family history of psychosis on age
at onset (F (1, 1003) = 0.30, P = 0.862). Also, there was no interaction
between cannabis use and family history of psychosis.
4. Discussion
In the present study, patients with a schizophrenia spectrum psy-
chosis and substance use had almost 3 years earlier onset of psychotic
symptoms, compared to patients without substance use. Earlier age at
onset was speciﬁcally related to cannabis use and not to any other sub-
stance use (including alcohol use), nor to gender or having a family his-
tory of psychosis. The results from the present study is in linewith other
studies reporting approximately 3 years earlier age at onset of positive
psychotic symptoms in patients with schizophrenia spectrum disorder
that have been using cannabis (Di Forti et al., 2013; Large et al., 2011).
What is new is that this study documents earlier age at onset in patients
with substance use in a relative large multi-site sample that allows for
the investigation of difference substances and for the inﬂuence of possi-
ble confounders.
Cannabis was used by 9 of 10 of the substance using patients. Of
note, there were moderately strong positive correlations between the
use of cannabis and amphetamines, cocaine and hallucinogens,
conﬁrming that these are somehow associated. However, each speciﬁc
substance could explain its own unique proportion of the variance in
the model, thus the speciﬁc substances are regarded as acceptable ro-
bust predictors. Although, the use of stimulants has previously been
shown to be signiﬁcantly related to age at onset (Power et al., 2013;
van der Meer et al., 2014), this was not replicated in the present study.
Earlier age at onset has also been reported in men compared to
women (Abel et al., 2010). It has been suggested that cannabis use for-
ward age at onset in women, reducing the gender differences (Allegri
et al., 2013; Donoghue et al., 2014). However, earlier age at onset was
not associated with female or male gender in the present study indicat-
ing that the association between cannabis use and onset age was the
same in both genders.
In the present study therewere no differences in regard to the distri-
bution of family history of psychosis in the substance using and absti-
nent patients groups. This has also been found in other studies
(Boydell et al., 2007; Proal et al., 2014), and indicates that the level of fa-
milial vulnerability may be the same in both groups. Most patients have
started using cannabis before psychosis breakthrough (Goldberger
et al., 2010; Myles et al., 2015; Rabinowitz et al., 1998; Sevy et al.,
2010; Stefanis et al., 2013), but developmental processes related to psy-
chosis itself can theoretically inﬂuence the disposition to take sub-
stances, and this is hard to test empirically. This relationship is further
complicated by shared vulnerability for substance use and psychosis
(Hartz et al., 2014).
Some limitations of the present study should be taken into consider-
ation. Information on whether substance use preceded or followed the
age at onset is relevant when attempting to establish a causal relation-
ship between cannabis use and onset of psychosis. Lower education
level in the substance users in the present study could indicate lower
economic status, which again could be linked to cannabis use. The rela-
tionship between and substance use and economic status may be bi-
directional (Sevy et al., 2010). In 18 cases “date of ﬁrst contact with psy-
chiatric services for a psychotic disorder”was used as a proxy for age at
Table 3
Bivariate correlations (Pearson's R) between sociodemographic factors, substance type and age at onset in 977 patients with non-affective psychosis.
Age at onset Gender Alcohol Cannabis Amphetamines Cocaine Hallucinogens Opiates
Age at onset 1.000 −.010 −.059 −.169 −.104 −.113 −.089 −.084
Gender 1.000 −.108 −.140 −.101 −.124 −.093
Alcohol 1.000 .242 .219 .245 .224 .146
Cannabis 1.000 .533 .490 .454 .277
Amphetamines 1.000 .650 .623 .423
Cocaine 1.000 .658 .425
Hallucinogens 1.000 .441
Opiates 1.000
Note. Only signiﬁcant associations are shown (P values b .05).
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toms due to treatment-delay (Breitborde et al., 2009). This study lacks
information concerning the duration of the prodromal period, which
could have shedmore light on the relationship between illness process-
es in regard to start of cannabis use. Furthermore, information on family
history of psychosis was based on patient report and the reliability of
this method has been questioned (Roy et al., 1996). Another limitation
is that a clinical rating of the alcohol use the last 6 months were used
as a predictor variable in the regression analysis, in this case, a lifetime
measure of alcohol use would have been a more valid measure for the
purpose of the present study.
The ﬁnding from the present study emphasizes cannabis as an envi-
ronmental factor associated with a 3 years earlier age at onset of psy-
chotic symptoms. No other illegal substance was related to earlier age
at onset, suggesting a speciﬁc effect of cannabis and a need for under-
standing the mechanism behind this relationship.
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